Report
From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis

https://doi.org/10.1016/j.jaad.2007.08.030Get rights and content

Background

Biologics are widely used in the treatment of psoriasis and psoriatic arthritis.

Objective

Our aim was to arrive at a consensus on the kind of monitoring and the vaccinations that should be performed before and during biologic therapy.

Methods

Medical literature and data presented at meetings were reviewed and a consensus conference was held by members of the Medical Board of the National Psoriasis Foundation.

Results

Consensus was established on monitoring and vaccination practices that included discussion and recognition of variations in those practices. History, physical examination, chemistry screen with liver function tests, complete blood cell count, and platelet count and tuberculosis testing are widely obtained at baseline and with variable frequencies thereafter. Patients treated with efalizumab have platelet counts checked more often; liver function tests are repeated more frequently in patients treated with infliximab; patients taking tumor necrosis factor blockers undergo tuberculosis testing more often; and patients treated with alefacept have CD4 counts checked approximately every 2 weeks. Avoidance of live vaccines during biologic therapy and administration of essential vaccines before biologic therapy were discussed, although vaccination is performed only to a variable degree. There was no consistency in the measurement of antinuclear antibodies among the experts.

Limitations

There are few evidence-based studies on monitoring practices for patients with psoriasis taking biologic therapies.

Conclusions

In patients taking biologic therapies for psoriasis, monitoring of blood chemistries, blood counts, CD4 counts, antinuclear antibodies, tuberculin skin tests, history, and physical examination may be warranted depending on the particular therapy and the particular patient. Vaccination practices are also addressed.

Section snippets

Methods

Members of the Medical Board of the National Psoriasis Foundation were surveyed about their monitoring and vaccination practices before patients with psoriasis are started on biologics. The survey also asked about the type and frequency of monitoring performed during therapy. The results of those surveys are reported in a separate article and were used as a basis for a consensus conference of the Foundation's medical board.4 In preparation for our consensus conference, we reviewed medical

History and physical examination

The need for history and physical examination was assessed. Elements brought into focus included medical history for tuberculosis (TB) exposure, other chronic infections, malignancy, and a review of systems (specifically neurologic, cardiac, and musculoskeletal [psoriatic arthritis]). Neurologic history is relevant as tumor necrosis factor (TNF)-α inhibitors can rarely be associated with new onset or exacerbation of demyelinating diseases such as multiple sclerosis and should, therefore, be

Discussion

Most studies of monitoring and vaccination practices in patients treated with biologics are not evidence based, making it difficult to create monitoring guidelines. There are few double-blind, placebo-controlled studies to show that monitoring or vaccinations prevent complications or disease. Several well-done studies help us predict which interventions are likely to find abnormal results. For example, pivotal trials with biologics were large enough to detect small numbers of cases of

References (136)

  • Halverstam CP, Lebwohl M. Practical management and monitoring of psoriasis in patients on biologic therapy. Psoriasis...
  • R. Steinbrook

    Guidance for guidelines

    N Engl J Med

    (2007)
  • N. Mohan et al.

    Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

    Arthritis Rheum

    (2001)
  • L. Bensouda-Grimaldi et al.

    Adalimumab-associated multiple sclerosis

    J Rheumatol

    (2007)
  • The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

    TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study

    Neurology

    (1999)
  • N. Al Saieg et al.

    Etanercept induced multiple sclerosis and transverse myelitis

    J Rheumatol

    (2006)
  • R. Noguera-Pons et al.

    Optic neuritis with concurrent etanercept and isoniazid therapy

    Ann Pharmacother

    (2005)
  • N.L. Sicotte et al.

    Onset of multiple sclerosis associated with anti-TNF therapy

    Neurology

    (2001)
  • T. Ruiz-Jimeno et al.

    Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab

    J Rheumatol

    (2006)
  • C. Richez et al.

    Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers

    Neurology

    (2005)
  • P.J. Enayati et al.

    Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis

    J Clin Gastroenterol

    (2005)
  • C.W. Thomas et al.

    Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease

    Inflamm Bowel Dis

    (2004)
  • B.W. van Oosten et al.

    Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2

    Neurology

    (1996)
  • H.J. Kwon et al.

    Case reports of heart failure after therapy with a tumor necrosis factor antagonist [review] [summary for patients in Ann Intern Med 2003;138:I48]

    Ann Intern Med

    (2003)
  • E.S. Chung et al.

    Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial

    Circulation

    (2003)
  • A.P. Coletta et al.

    Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH

    Eur J Heart Fail

    (2002)
  • B. Bozkurt et al.

    Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure

    Circulation

    (2001)
  • M.H. Schiff et al.

    Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

    Ann Rheum Dis

    (2006)
  • D.L. Mann et al.

    Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL)

    Circulation

    (2004)
  • G.W. Moe et al.

    In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure

    Am J Physiol Heart Circ Physiol

    (2004)
  • J. Cole et al.

    The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists

    Rheumatol Int

    (2007)
  • Alefacept (Amevive) [package insert]

    (2006)
  • Efalizumab (Raptiva) [package insert]

    (2006)
  • Etanercept (Enbrel) [package insert]

    (2007)
  • Infliximab (Remicade) [package insert]

    (2006)
  • Adalimumab (Humira) [package insert]

    (2007)
  • P. Geborek et al.

    Tumor necrosis factor blockers do not increase overall tumor risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

    Ann Rheum Dis

    (2005)
  • S.L. Brown et al.

    Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

    Arthritis Rheum

    (2002)
  • L. Quartuccio et al.

    Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization

    Haematologica

    (2006)
  • A.C. Mackey et al.

    Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

    J Pediatr Gastroenterol Nutr

    (2007)
  • R. Thonhofer et al.

    Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment

    Ann Rheum Dis

    (2005)
  • E. Roddy et al.

    Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab

    Rheumatology (Oxford)

    (2002)
  • J. Askling et al.

    Hematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists

    Ann Rheum Dis

    (2005)
  • F. Wolfe et al.

    Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

    Arthritis Rheum

    (2004)
  • L. Biancone et al.

    Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicenter matched pair study

    Gut

    (2006)
  • A.C. Esser et al.

    Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab

    J Am Acad Dermatol

    (2004)
  • M. Lebwohl et al.

    No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years

    Arch Dermatol

    (2005)
  • J. Kuruvilla et al.

    Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor [erratum in Eur J Haematol 2004;72:306]

    Eur J Haematol

    (2003)
  • W.L. Tom et al.

    Efalizumab-induced autoimmune pancytopenia

    Br J Dermatol

    (2006)
  • T.E. Warkentin et al.

    Immune thrombocytopenia associated with efalizumab therapy for psoriasis

    Ann Intern Med

    (2005)
  • Cited by (0)

    Funding sources: None.

    Disclosure: Dr Lebwohl has been a consultant for Abbott, Amgen, Astellas, Centocor, Genentech, and Wyeth; he has been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Strober has been a speaker, advisor, consultant, and/or investigator for Abbott, Amgen, Astellas, Genentech, Centocor, and Wyeth. Dr Gelfand has been a consultant to Genentech, Centocor, Amgen, Wyeth, and Warner-Chilcott2, and has received grants from Biogen Idec, Amgen, Astellas, and Centocor. Dr Bagel has been a speaker for Amgen, Astellas, Genentech, and Abbott; he has been a clinical investigator for Centocor and Amgen. Dr Weinstein is an investigator for Abbott Labs, Amgen, Genentech, and Centocor. Dr Krueger has received fees as a consultant or advisory board member for Abbot, Almirall, Alza, Amgen, Astellas, Barrier Therapeutics, Boehringer-Ingelheim, Bristol-Myers Squibb, Centocor, Connetics, Genentech, Genzyme, L'Oreal, Magen Biosciences, MedaCorp, Medics, Novartis, Schering-Plough, Warner Chilcott, and ZARS. He owns equities and stock options in/from ZARS. In the last 24 months, Dr. Krueger has received lecture fees from Abbott, Amgen, Astellas, Boehringer-Ingelheim, Centocor, Connetics, and Warner Chilcott, and has received partial stipend support for a clinical research fellowship from Abbott, Amgen, and Centocor. Ms Young has been a consultant or speaker for Astellas, Abbott, Amgen, and Genentech. Dr Gordon has received research support and honoraria from, and has consulted for Abbott, Amgen, and Centocor. Dr Kalb has been an investigator and consultant for Abbott, Amgen, Centocor, and Genentech. Dr Hsu has served on advisory boards for Abbott, Centocor, Biogen Idec, Genentech, and Amgen and has been an investigator for Centocor and Amgen. Dr Mease has been an investigator, consultant, and speaker for Abbott, Amgen, Biogen Idec, Centocor, Genentech, and Wyeth. Dr Korman is an investigator, speaker, and consultant for Abbott, Astellas, Genentech; an investigator and speaker for Amgen; and an investigator and consultant for Centocor. Dr Kimball has been a consultant and investigator for Amgen, Centocor, and Abbott and has received a fellowship grant from Centocor. Dr Pariser has been an investigator and consultant for Abbott, Amgen, Astellas, Centocor, Genentech, and Warner Chilcott. Dr Gladman is a consultant for Abbott, Amgen, Bristol-Myers Squibb, Centocor, Schering, Wyeth, and has received grant support from Abbott Canada, Amgen-Wyeth Canada, Schering Canada, Pfizer Canada, and Wyeth Global for studies. Dr Van Voorhees has been an advisor for, and received honoraria from Amgen, Abbott, Centocor, and Genentech. Dr Paller has been a consultant for Astellas, Novartis, Amgen, and Johnson & Johnson, and has served on advisory boards for Astellas, Novartis, and Johnson & Johnson. Dr Ritchlin has been a consultant for Abbott, Wyeth, Amgen, Centocor, Biogen, and Genentech and has received research funding from Centocor. Dr Horn was an employee of the National Psoriasis Foundation. The National Psoriasis Foundation receives unrestricted funding from Abbott Immunology, Amgen and Wyeth, Astellas Pharma Inc, Barrier Therapeutics, Beiersdorf, Centocor, Daavlin, Galderma Laboratories, Genentech, National Biologic Corporation, Neutrogena, PhotoMedex, Stiefel Laboratories, and Warner Chilcott. Dr Morison has no conflicts of interest to declare.

    Reprints not available from the authors.

    View full text